{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:13:47Z","timestamp":1751429627888,"version":"3.41.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05149-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:17:58Z","timestamp":1751375878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers"],"prefix":"10.1038","volume":"15","author":[{"given":"Shogo","family":"Adomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurie","family":"Kura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A","family":"De Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saizo","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhisa","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Banno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"5149_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/cncr.29841","volume":"122","author":"SC Kamran","year":"2016","unstructured":"Kamran, S. C., De Gonzalez, A. B., Ng, A., Haas-Kogan, D. & Viswanathan, A. N. Therapeutic radiation and the potential risk of second malignancies. Cancer 122, 1809\u20131821 (2016).","journal-title":"Cancer"},{"key":"5149_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/01.ju.0000107247.81471.06","volume":"171","author":"MR Cooperberg","year":"2004","unstructured":"Cooperberg, M. R. et al. The contemporary management of prostate cancer in the united states: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 171, 1393\u20131401 (2004).","journal-title":"J Urol."},{"key":"5149_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.juro.2007.08.157","volume":"179","author":"PJ Bostrom","year":"2008","unstructured":"Bostrom, P. J., Soloway, M. S., Manoharan, M., Ayyathurai, R. & Samavedi, S. Bladder cancer after radiotherapy for Prostate cancer: Detailed analysis of pathological features and outcome after radical cystectomy. J Urol. 179, 91\u201395 (2008).","journal-title":"J Urol."},{"key":"5149_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.urology.2021.03.033","volume":"154","author":"ST Sha","year":"2021","unstructured":"Sha, S. T. et al. Clinical characterization of radiation-associated muscle-invasive bladder cancer. Urology 154, 208\u2013214 (2021).","journal-title":"Urology"},{"key":"5149_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.juro.2006.10.071","volume":"177","author":"S Boorjian","year":"2007","unstructured":"Boorjian, S. et al. Bladder cancer incidence and risk factors in men with prostate Cancer: Results from Cancer of the Prostate Strategic Urologic Research Endeavor. J. Urol. 177, 883\u2013888 (2007).","journal-title":"J. Urol."},{"key":"5149_CR6","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.juro.2008.07.038","volume":"180","author":"AM Nieder","year":"2008","unstructured":"Nieder, A. M., Porter, M. P. & Soloway, M. S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J. Urol. 180, 2005\u20132010 (2008).","journal-title":"J. Urol."},{"key":"5149_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00345-016-1934-z","volume":"35","author":"A Keehn","year":"2016","unstructured":"Keehn, A., Ludmir, E., Taylor, J. & Rabbani, F. Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality. World J. Urol. 35, 713\u2013720 (2016).","journal-title":"World J. Urol."},{"key":"5149_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00345-023-04380-5","volume":"41","author":"T Minami","year":"2023","unstructured":"Minami, T. et al. External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy. World J. Urol. 41, 1317\u20131321 (2023).","journal-title":"World J. Urol."},{"key":"5149_CR9","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1126\/science.1260200","volume":"347","author":"S Borah","year":"2015","unstructured":"Borah, S. et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 347, 1006\u20131010 (2015).","journal-title":"Science"},{"key":"5149_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1158\/1541-7786.MCR-16-0003","volume":"14","author":"RJA Bell","year":"2016","unstructured":"Bell, R. J. A. et al. Understanding TERT Promoter Mutations: a common path to immortality. Mol. Cancer Res. 14, 315\u2013323 (2016).","journal-title":"Mol. Cancer Res."},{"key":"5149_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","volume":"65","author":"Y Allory","year":"2014","unstructured":"Allory, Y. et al. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome. Eur. Urol. 65, 360\u2013366 (2014).","journal-title":"Eur. Urol."},{"key":"5149_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41585-018-0001-5","volume":"15","author":"C G\u00fcnes","year":"2018","unstructured":"G\u00fcnes, C., Wezel, F., Southgate, J. & Bolenz, C. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nat. Rev. Urol. 15, 386\u2013393 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"5149_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/his.14038","volume":"76","author":"DR Levy","year":"2020","unstructured":"Levy, D. R. & Cheng, L. The expanding molecular and mutational landscape of nested variant of urothelial carcinoma. Histopathology 76, 638\u2013639 (2020).","journal-title":"Histopathology"},{"issue":"513","key":"5149_CR14","first-page":"e13","volume":"76","author":"G Ploussard","year":"2010","unstructured":"Ploussard, G. et al. Prognostic value of loss of heterozygosity at chromosome 9P in non\u2013muscle-invasive bladder cancer. Urology 76(513), e13-513.e18 (2010).","journal-title":"Urology"},{"key":"5149_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.eururo.2004.12.018","volume":"47","author":"S Kr\u00fcger","year":"2005","unstructured":"Kr\u00fcger, S., Mahnken, A., Kausch, I. & Feller, A. C. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur. Urol. 47, 463\u2013467 (2005).","journal-title":"Eur. Urol."},{"key":"5149_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jss.2007.01.012","volume":"143","author":"R Bartoletti","year":"2007","unstructured":"Bartoletti, R. et al. Loss of P16 expression and chromosome 9P21 LOH in predicting outcome of patients affected by superficial bladder cancer. J. Surg. Res. 143, 422\u2013427 (2007).","journal-title":"J. Surg. Res."},{"key":"5149_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.urolonc.2009.04.019","volume":"28","author":"M Castillo-Martin","year":"2010","unstructured":"Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. & Cordon-Cardo, C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol. 28, 401\u2013408 (2010).","journal-title":"Urol. Oncol."},{"key":"5149_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2014","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25\u201341 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"5149_CR19","unstructured":"Amin MB, et al. AJCC Cancer Staging Manual, eighth ed. (2017)."},{"key":"5149_CR20","doi-asserted-by":"crossref","unstructured":"Moch H, et al. WHO classification of tumours of urinary system and male genital organs, fourth ed. (2016).","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"5149_CR21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/cas.14000","volume":"110","author":"Y Hayashi","year":"2019","unstructured":"Hayashi, Y. et al. Diagnostic potential of TERT promoter and FGFR 3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Cancer Sci. 110, 1771\u20131779 (2019).","journal-title":"Cancer Sci."},{"key":"5149_CR22","doi-asserted-by":"crossref","unstructured":"Hayashi Y, et al. Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer. Sci. Rep. 12, (2022).","DOI":"10.1038\/s41598-022-21158-8"},{"key":"5149_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2017.07.013","volume":"405","author":"K Sakai","year":"2017","unstructured":"Sakai, K. et al. Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer Lett. 405, 22\u201328 (2017).","journal-title":"Cancer Lett."},{"key":"5149_CR24","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/cancers12113382","volume":"12","author":"T Noguchi","year":"2020","unstructured":"Noguchi, T. et al. Comprehensive Gene Mutation Profiling of circulating tumor DNA in ovarian Cancer: Its Pathological and Prognostic Impact. Cancers (Basel). 12, 3382 (2020).","journal-title":"Cancers (Basel)."},{"key":"5149_CR25","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak, E. J. et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur. Urol. 72, 952\u2013959 (2017).","journal-title":"Eur. Urol."},{"issue":"2","key":"5149_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley, K. A. et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173(2), 291-304.e6. https:\/\/doi.org\/10.1016\/j.cell.2018.03.022 (2018).","journal-title":"Cell"},{"issue":"3","key":"5149_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott, K. et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 6(3), 271-281.e7. https:\/\/doi.org\/10.1016\/j.cels.2018.03.002 (2018).","journal-title":"Cell Syst."},{"issue":"4","key":"5149_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor, A. M. et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33(4), 676-689.e3. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.007 (2018).","journal-title":"Cancer Cell"},{"issue":"2","key":"5149_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173(2), 400-416.e11. https:\/\/doi.org\/10.1016\/j.cell.2018.02.052 (2018).","journal-title":"Cell"},{"issue":"2","key":"5149_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2), 321-337.e10. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035 (2018).","journal-title":"Cell"},{"issue":"1","key":"5149_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao, Q. et al. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 23(1), 227-238.e3. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.050 (2018).","journal-title":"Cell Rep."},{"issue":"7800","key":"5149_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2095-1","volume":"579","author":"GD Poore","year":"2020","unstructured":"Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579(7800), 567\u2013574 (2020).","journal-title":"Nature"},{"issue":"2","key":"5149_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2018.03.033","volume":"173","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173(2), 305-320.e10. https:\/\/doi.org\/10.1016\/j.cell.2018.03.033 (2018).","journal-title":"Cell"},{"key":"5149_CR34","doi-asserted-by":"crossref","unstructured":"Bonneville R, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. (2017).","DOI":"10.1200\/PO.17.00073"},{"issue":"1","key":"5149_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1464-410X.2006.06182.x","volume":"98","author":"JS Sandhu","year":"2006","unstructured":"Sandhu, J. S. et al. Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int. 98(1), 59\u201362. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06182.x (2006).","journal-title":"BJU Int."},{"key":"5149_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.12.003","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa, A. et al. Incidence and Outcomes of Secondary Bladder Cancer Following Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. Focus. https:\/\/doi.org\/10.1016\/j.euf.2024.12.003 (2025).","journal-title":"Eur. Urol. Focus."},{"key":"5149_CR37","doi-asserted-by":"crossref","unstructured":"Hayashi Y, Fujita K, Netto GJ, Nonomura N. Clinical application of TERT promoter mutations in urothelial carcinoma. Front Oncol. 11, (2021).","DOI":"10.3389\/fonc.2021.705440"},{"key":"5149_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2021.12.004","volume":"81","author":"M Mossanen","year":"2022","unstructured":"Mossanen, M. et al. Genomic features of muscle-invasive bladder cancer arising after prostate radiotherapy. Eur. Urol. 81, 466\u2013473 (2022).","journal-title":"Eur. Urol."},{"key":"5149_CR39","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/ijc.29526","volume":"137","author":"I Hosen","year":"2015","unstructured":"Hosen, I. et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int. J. Cancer. 137, 1621\u20131629 (2015).","journal-title":"Int. J. Cancer."},{"key":"5149_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2013.10.038","volume":"65","author":"S Wu","year":"2014","unstructured":"Wu, S. et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and Molecular study. Eur. Urol. 65, 274\u2013277 (2014).","journal-title":"Eur. Urol."},{"key":"5149_CR41","doi-asserted-by":"publisher","first-page":"17426","DOI":"10.1073\/pnas.1310522110","volume":"110","author":"PS Rachakonda","year":"2013","unstructured":"Rachakonda, P. S. et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. U S A. 110, 17426\u201317431 (2013).","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"77","key":"5149_CR42","first-page":"e17","volume":"38","author":"J Roggisch","year":"2020","unstructured":"Roggisch, J., Ecke, T. & Koch, S. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urol. Oncol. 38(77), e17-77.e25 (2020).","journal-title":"Urol. Oncol."},{"key":"5149_CR43","doi-asserted-by":"crossref","unstructured":"Shuai H, Duan X, Zhou J-J, Liu Y, Wu, T. Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis. BMC Urol. 23, (2023).","DOI":"10.1186\/s12894-023-01349-9"},{"key":"5149_CR44","doi-asserted-by":"publisher","first-page":"101629","DOI":"10.1016\/j.tranon.2023.101629","volume":"29","author":"H-P Liu","year":"2023","unstructured":"Liu, H.-P. et al. Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature. Transl. Oncol. 29, 101629 (2023).","journal-title":"Transl. Oncol."},{"key":"5149_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of Muscle-Invasive Bladder Cancer. Cell 171, 540-556.e25 (2017).","journal-title":"Cell"},{"key":"5149_CR46","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1200\/JCO.2003.05.073","volume":"21","author":"BWG Van Rhijn","year":"2003","unstructured":"Van Rhijn, B. W. G. et al. Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome. J. Clin. Oncol. 21, 1912\u20131921 (2003).","journal-title":"J. Clin. Oncol."},{"key":"5149_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.febslet.2004.06.011","volume":"569","author":"HJ Kee","year":"2004","unstructured":"Kee, H. J. et al. Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma. FEBS Lett. 569, 307\u2013316 (2004).","journal-title":"FEBS Lett."},{"key":"5149_CR48","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s12328-022-01649-x","volume":"15","author":"Y Masaki","year":"2022","unstructured":"Masaki, Y. et al. Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma. Clin. J. Gastroenterol. 15, 809\u2013817 (2022).","journal-title":"Clin. J. Gastroenterol."},{"key":"5149_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2220\/biomedres.39.159","volume":"39","author":"K Hatakeyama","year":"2018","unstructured":"Hatakeyama, K. et al. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing. Biomed. Res. 39, 159\u2013167 (2018).","journal-title":"Biomed. Res."},{"key":"5149_CR50","first-page":"362","volume":"39","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 39, 362 (2018).","journal-title":"Science"},{"key":"5149_CR51","first-page":"7","volume":"362","author":"PR Davidson","year":"2017","unstructured":"Davidson, P. R., Sherborne, A. L., Taylor, B., Nakamura, A. O. & Nakamura, J. L. A pooled mutational analysis identifies ionizing radiation-associated mutational signatures conserved between mouse and human malignancies. Sci. Rep. 362, 7 (2017).","journal-title":"Sci. Rep."},{"key":"5149_CR52","doi-asserted-by":"crossref","unstructured":"Zhang T, et al. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. (2020).","DOI":"10.1002\/cncr.33067"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05149-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:18:04Z","timestamp":1751375884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05149-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5149"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05149-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval of the research protocol by an institutional review board: This study protocol was approved and the requirement for written informed consent was waived by the Institutional Review Board of Kindai University (IRB # R02-155) due to the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"20495"}}